Financials

10x Genomics Inc. financials

TXG Life Sciences Tools and Services

10x Genomics Inc., founded in 2012 and headquartered in Pleasanton, California, United States, provides advanced genomic analysis systems that focus on single-cell and spatial genomics. The company’s primary revenue comes from its flagship Chromium system and recurring consumable sales, supporting cutting-edge research across academic and clinical settings. Led by CEO Serge Saxena since 2019, it holds a strong market position with significant technological advantages. Future growth is being driven by innovations in next-generation platforms and expanded market strategies.

Snapshot

10x Genomics Inc. reported $643M in revenue in fiscal 2025, up 5.2% year over year, with an operating margin of -9.5%.

Revenue (FY2025): $643M
YoY growth: +5.2%
Operating margin: -9.5%
Direction: Expanding

Financial statements

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenues	642,823	610,785	618,727	516,409
Cost of Sales	198,942	196,303	209,414	120,386
Gross Profit	443,881	414,482	409,313	396,023
Selling, General & Administrative Expenses	316,134	344,343	343,330	298,300
Research & Development Expenses	238,632	264,698	270,332	265,667
Other Operating Expenses	49,900	—	60,980	—
Operating Profit	(60,985)	(194,559)	(265,329)	(167,944)
Interest and Investment Income	20,048	18,930	16,885	6,647
Interest Expense	—	(4)	(33)	(476)
Non-Operating Income	1,030	(2,067)	(286)	(198)
Total Non-Operating Income	21,078	16,859	16,566	5,973
Income Before Provision for Income Taxes	(39,907)	(177,700)	(248,763)	(161,971)
Provision for Income Taxes	3,637	4,927	6,336	4,029
Consolidated Net Income	(43,544)	(182,627)	(255,099)	(166,000)
Net Income Attributable to Common Shareholders	(43,544)	(182,627)	(255,099)	(166,000)
Basic EPS	-0.35	-1.52	-2.18	-1.46
Diluted EPS	-0.35	-1.52	-2.18	-1.46
Basic Weighted Average Shares Outstanding	124,750	120,452	117,165	113,859
Diluted Weighted Average Shares Outstanding	124,750	120,452	117,165	113,859
Shares Outstanding	127,691	122,292	119,095	115,195

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Cash and Cash Equivalents	473,966	344,067	359,284	219,746
Short-Term Investments	49,443	49,335	29,411	212,871
Total Cash and Cash Equivalents	523,409	393,402	388,695	432,617
Accounts Receivable	47,013	87,862	114,832	104,211
Other Receivables	35,480	606	—	—
Total Trade Receivables	82,493	88,468	114,832	104,211
Inventories	56,341	83,107	73,706	81,629
Other Current Assets	22,208	19,410	18,789	16,578
Total Current Assets	684,451	584,387	596,022	635,035
Net Property, Plant & Equipment	287,161	309,938	344,932	359,210
Net Intangible Assets	62,329	15,671	16,616	22,858
Goodwill	4,511	4,511	4,511	4,511
Other Long-Term Assets	2,913	4,129	3,062	7,366
Total Assets	1,041,370	918,636	965,143	1,028,980
Accounts Payable	12,733	12,909	15,738	21,599
Accrued Expenses	82,471	74,780	86,753	92,454
Current Portion of Leases	10,985	9,286	11,521	9,037
Unearned Revenue	23,902	20,658	13,150	7,867
Other Current Liabilities	23,363	—	—	—
Total Current Liabilities	153,454	117,633	127,162	130,957
Leases	73,376	73,327	83,849	86,139
Other Long-Term Liabilities	18,209	17,542	13,089	6,141
Total Long-Term Liabilities	91,585	90,869	96,938	92,280
Total Liabilities	245,039	208,502	224,100	223,237
Common Stock	2	2	2	2
Additional Paid-in Capital	2,306,690	2,177,670	2,025,890	1,839,400
Accumulated Other Comprehensive Income	225	(493)	(429)	(4,335)
Retained Earnings	(1,510,590)	(1,467,050)	(1,284,420)	(1,029,320)
Total Common Shareholders' Equity	796,326	710,134	741,043	805,743
Total Shareholders' Equity	796,326	710,134	741,043	805,743
Total Liabilities and Shareholders' Equity	1,041,370	918,636	965,143	1,028,980

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	(43,544)	(182,627)	(255,099)	(166,000)
Depreciation & Amortization	43,816	43,708	43,619	33,006
Share-Based Compensation Expense	109,118	140,749	166,950	136,848
Other Adjustments	1,721	3,580	11,990	1,957
Changes in Trade Receivables	6,440	26,951	(10,613)	(18,948)
Changes in Inventories	27,953	(9,777)	7,871	(21,192)
Changes in Accounts Payable	(2,126)	(3,354)	(6,017)	5,858
Changes in Accrued Expenses	2,494	(9,082)	25,664	4,450
Changes in Unearned Revenue	746	11,209	10,932	3,350
Changes in Other Operating Activities	(10,568)	(14,693)	(10,494)	(12,935)
Cash from Operating Activities	136,050	6,664	(15,197)	(33,606)
Capital Expenditure	(5,935)	(12,393)	(48,601)	(131,661)
Purchases of Intangible Assets	—	(1,000)	(923)	—
Purchases of Investments	(123,435)	(48,876)	—	(282,871)
Proceeds from Sale of Investments	125,200	29,638	183,016	67,645
Payments for Business Acquisitions	(9,268)	—	—	(4,000)
Cash from Investing Activities	(13,438)	(32,631)	133,492	(350,887)
Issuance of Common Shares	6,803	10,914	19,483	21,226
Net Issuance / (Repurchases) of Common Shares	6,803	10,914	19,483	21,226
Other Financing Activities	—	—	(5,814)	(5,409)
Cash from Financing Activities	6,803	10,914	13,669	15,817
Effect of Exchange Rate Changes on Cash and Cash Equivalents	484	(164)	(33)	(44)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash	129,899	(15,217)	131,931	(368,720)

Key metrics

$2.08B

Market Cap

-46.60x

P/E

3.24x

P/S

-95.73x

EV/EBITDA

-5.8%

Return on Equity

-15.5%

Return on Invested Capital

4.46x

Current Ratio

20.2%

Free Cash Flow Margin

Quarterly trend

Quarter	Revenue	YoY growth	Operating margin	Operating income
Q1 2026	$151M	+-2.6%	-11.3%	$-17M
Q4 2025	$166M	+0.6%	-11.8%	$-20M
Q3 2025	$149M	+-1.7%	-21.6%	$-32M
Q2 2025	$173M	+12.9%	17.4%	$30M
Q1 2025	$155M	—	-25.4%	$-39M
Q4 2024	$165M	—	-30.2%	$-50M
Q3 2024	$152M	—	-27.4%	$-41M
Q2 2024	$153M	—	-27.3%	$-42M

Margins

69.1%

Gross margin

-9.5%

Operating margin

-6.8%

Net margin

Snapshot

Financial statements

Key metrics

Quarterly trend

Margins

More on 10x Genomics Inc.

See how VectorShift works for your firm